Rockville, Md. (April 23, 2024) – Cellphire Therapeutics, Inc., a clinical stage biotechnology company developing next-generation allogeneic cellular therapeutics, today announced the United States Patent and Trademark Office (USPTO) issued a patent, entitled Platelets Loaded with Anti-Cancer Agents (US Patent 11,965,178 B2 ('178 Patent) covering innovation in the use of Freeze-Dried Platelet-Derived Hemostat Technology (FPH) and/or FPH technology loaded with anti-cancer compounds for treating several cancers efficaciously while reducing toxicity. FPH, also known as Thrombosomes®, is a novel, shelf-stable hemostatic agent currently in Phase II clinical trials.
"This patent expands upon our core hemostatic cell preservation technology and is the first issued innovation for stably loading platelets with anti-cancer agents as a novel drug delivery system that potentially improves efficacy while mitigating off-target effects. FPH unique mechanism of action and stability allows for treatment of severe rare cancers where standard platelets are ineffective.” said Keith Moskowitz, VP of Discovery and Research. The issuance of the ‘178 patent also demonstrates novel applications of anti-cancer loaded stabilized platelet derivatives provides protection through 2041 and further demonstrates Cellphire Therapeutics’ emphasis on innovation and our ability to develop unique intellectual property.
About Cellphire Therapeutics
Cellphire Therapeutics, Inc. is a biotechnology company developing next-generation allogeneic cellular therapeutics. The company is applying its proprietary cell stabilization technology first to platelets, to develop lifesaving products. Its lead investigational product is Thrombosomes®, a freeze-dried hemostatic derived from human platelets. Cellphire’s technologies support a wide range of potential medical applications for Orphan populations to surgical, trauma, traumatic brain injury (TBI) and intercranial hemorrhage (ICH) unmet clinical needs, among other things. For more information, visit www.cellphire.com.
Robert Woods
VP, Business Operations
RWoods@cellphire.com